Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We utilise our cutting-edge, exclusive workflow to develop focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q8IVJ1

UPID:
S41A1_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
Q8IVJ1; Q63HJ4; Q658Z5; Q659A4; Q6MZK2

BACKGROUND:
The protein Solute carrier family 41 member 1, known as SLC41A1, operates as a Na(+)/Mg(2+) ion exchanger, crucial for Mg(2+) efflux across the plasma membrane. Its function is directly influenced by the Na(+) gradient, established by the Na(+)/K(+) pump. SLC41A1 is instrumental in generating cellular Mg(2+) fluxes that regulate circadian rhythms of gene expression and metabolism, facilitating the body's energetic needs throughout the day. Additionally, it modulates the activity of ATP-dependent enzymes involved in vital metabolic pathways.

THERAPEUTIC SIGNIFICANCE:
Given SLC41A1's link to Nephronophthisis-like nephropathy 2, a condition characterized by cystic kidney disease and renal failure, its study is pivotal for drug discovery. Understanding the role of SLC41A1 could open doors to potential therapeutic strategies, offering hope for patients suffering from this and potentially other metabolic and renal diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.